<DOC>
	<DOCNO>NCT01530048</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial test bioequivalence insulin aspart 100 U/mL ( U100 ) formulation new insulin aspart 200 U/mL ( U200 ) formulation .</brief_summary>
	<brief_title>Bioequivalence Two Insulin Aspart Formulations ( 100 U/mL Versus 200 U/mL )</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Considered healthy judge vital sign , medical history , ECG ( electrocardiogram ) , laboratory value , physical examination Body mass index 18 27 kg/m^2 ( inclusive ) Nonsmoker Fasting blood glucose maximum 6 mmol/L HbA1c 6.4 % Pregnant breastfeeding woman Women use acceptable method contraception without difficulty least three month prior trial start ( screen ) , include intrauterine device , oral contraceptive , hormonal implant , sterilisation Clinically significant abnormal laboratory value ( judge Investigator ) Close relative type 1 diabetes mellitus ( father , mother , sister brother ) Intake alcohol within last 24 hour prior screen drug administration visit Blood donation blood loss 500 mL within 3 last month screen Strenuous exercise within 48 hour screen well drug administration followup Smoking past month drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>